立方制药：取得美沙拉秦肠溶片药品注册证书

Core Viewpoint - The approval of Mesalazine enteric-coated tablets by the National Medical Products Administration enhances the company's product pipeline and market competitiveness [1] Company Summary - The company, Lifan Pharmaceutical (003020.SZ), has received the drug registration certificate for Mesalazine enteric-coated tablets, which are indicated for the treatment of acute exacerbations of ulcerative colitis and maintenance therapy to prevent recurrence, as well as for acute exacerbations of Crohn's disease [1] - As of the announcement date, in addition to imported products and the company, there are four domestic enterprises holding the same specification drug approval, and three others holding approvals for different specifications [1]